Bioinformatics & Computational Biology
This group builds scalable algorithms and machine‑learning frameworks to analyze genomics, transcriptomics, proteomics, and single‑cell data. They integrate heterogeneous datasets to construct predictive models of cellular behavior.
Their software pipelines and visualization tools empower collaborators across the institute to extract actionable insights, accelerate discovery, and foster data‑driven decision‑making in biotech research.
Cellular Signal Transduction
This group investigates the molecular pathways by which cells perceive and respond to external and internal cues. By mapping key receptors, kinases, and second messengers, they aim to reveal how normal signaling maintains homeostasis and how its dysregulation leads to disease.
Their work lays the groundwork for novel diagnostics and targeted therapies in areas such as neurodegeneration, metabolic disorders, and inflammatory conditions.
Genome Editing & Epigenetics
Focusing on CRISPR/Cas systems and emerging base‑editing platforms, this team refines tools for safely rewriting the genome. They also explore how epigenetic modifications influence gene expression, cell fate, and heritable traits.
Their dual approach promises precision medicines for genetic disorders, strategies to reverse pathogenic epigenetic marks, and advances in regenerative biology.
Algae‑Based Biofuel and Bioproduct Synthesis
This research optimizes algal strain selection and photobioreactor conditions to maximize lipid yields and valuable co‑metabolites. Process engineering focuses on cost‑effective scale‑up, while green extraction techniques recover biofuels and bioplastics. The project addresses both energy security and circular‑economy goals.
Enzyme‑Driven Plastic Waste Bioremediation
Combining directed evolution and computational modeling, we develop enzymes capable of rapidly breaking down PET and related plastics. Studies will assess catalytic efficiency, thermal stability, and integration into safe microbial chassis. Pilot‑scale demonstrations aim to validate environmental impact and biorecycling potential.
Patient‑Derived Organoid Platforms for Personalized Medicine
By growing mini‑organs from patient biopsy samples, we create high‑throughput drug screens tailored to each individual’s tumor or genetic disease. Integrated genomic and pharmacodynamic analyses will pinpoint optimal therapies. This approach seeks to streamline personalized treatment decisions in clinical settings.
Smart Nanocarrier Platforms for Targeted Drug Delivery
This project engineers stimuli‑responsive nanocarriers that only release their payload at disease sites, leveraging pH‑ and enzyme‑sensitive polymers. In vitro assays and animal models will evaluate biodistribution, controlled release kinetics, and therapeutic efficacy. The ultimate goal is a safe, scalable platform for precision medicine applications.
Frequently asked questions
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.